Ning Zhou
Huazhong University of Science and Technology, ChinaTitle: Long-term Effects of Nicorandil Combined with Dihydropyridine Calcium Channel Blockers on Cardiovascular Outcomes in Patients with Coronary Heart Disease: A Real-world Observational Study
Abstract
A multicenter, retrospective, real-world study was conducted. Between August 2002 and March 2020, 7413 eligible patients with CHD were divided into DHP-CCB plus nicorandil combination (n = 1843) and DHP-CCB (n = 5570) treatment groups. The primary outcome was MACE, defined as a composite of myocardial infarction, stroke, and all-cause mortality. Propensity score matching was used to adjust for confounding factors. After propensity score matching, combination therapy, compared with DHP-CCBs alone, was associated with a lower risk of MACE (HR: 0.80, 95% CI: .67–0.97). The combination group also had a lower risk of stroke (HR: 0.55, 95% CI: 0.44–0.69), but not myocardial infarction (HR: 1.21, 95% CI: 0.91 1.61) or all-cause mortality (HR: 1.24, 95% CI: 0.63–2.44). Subgroup analysis revealed more prominent benefits of the combined treatment on MACE in patients with than without diabetes. The combination of nicorandil and DHP-CCBs may be more beneficial than DHP-CCBs alone in decreasing long-term risks of MACE and stroke in patients with CHD.
Biography
Ning Zhou completed his PhD at the age of 29 years from Fudan University, China. He is the associated professor and attending physician of Cardiology Department, Tongji Hospital, Tongji Medical College, HUST. He has over 44 publications, and his publication h-index is 6.8. He has been serving as an editorial board member of several reputed journals.
Organization Location
1309 Coffeen Avenue, STE 1200, Sheridan, Wyoming 82801, USA
Mail us at
Program Enquiry
cardiacare@scientexconferences.com
General Enquiry
contact@scientexconferences.com
Registration Enquiry
finance@scientexconferences.com
cardiacare@scientexevents.org
Our Social Presence
Call us at
USA : (+1) 914 520 5013